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Vaccination with different heat shock proteins (HSP60,
HSP65) prevented the development of low-dose strepto-
zotocin (STZ)-induced autoimmune diabetes in C57BL/
KSJ mice. The aim of our work was to examine whether
the vaccination with HSP65 can prevent the well-known
cardiac electrophysiological characteristics of diabetes.
The electrophysiological effects of dofetilide (a class III
antiarrhythmic drug) were also studied. Diabetes was
induced by a low dose of STZ (3 × 30 mg/kg i.p.), the vac-
cination with HSP65 (100 μg/animal) occurred 7 days
before STZ treatment. The parameters of transmembrane
action potentials (APs) of right ventricular papillary mus-
cles in rats were studied by the microelectrode technique.
The previously observed prolongation of AP duration in
diabetes induced by a high dose of STZ was recorded in
the case of low dose of STZ too. The vaccination with
HSP65 could not modify the increase of AP duration.
Dofetilide (1–10 μM) did not cause any significant altera-
tions in the parameters of AP either in diabetic or in the
HSP-treated animals. Our results with dofetilide differ
from published data. This result could be due to the fact
that the ion current characteristic of the rat ventricular
repolarization phase highly differs from that of other spe-
cies. We need further experiments to find out additional
explanations of our results.
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